

Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from Recent Major Conferences

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Ifinatamab deruxtecan (I-DXd) targets which of the following?**
 - a. HER2
 - b. HER3
 - c. TROP2
 - d. B7-H3**
- 2. What was the approximate intracranial progression-free survival (PFS) rate observed with repotrectinib for patients with ROS1 tyrosine kinase inhibitor-naïve advanced non-small cell lung cancer (NSCLC) with ROS1 fusion in the Phase I/II TRIDENT trial?**
 - a. 30%
 - b. 50%
 - c. 75%
 - d. 90%**
- 3. What was the hazard ratio for PFS with ivonescimab versus pembrolizumab as first-line therapy for PD-L1 positive lung cancer in the Phase III HARMONi-2 trial?**
 - a. 0.51**
 - b. 0.69
 - c. 0.77
 - d. 0.89
- 4. Which of the following best reflects the current regulatory status of tumor treating fields for metastatic NSCLC?**
 - a. Investigational
 - b. FDA approved in combination with PD-1/PD-L1 inhibitors or docetaxel for patients who experienced disease progression on or after a platinum-based regimen**
 - c. FDA approved in combination with PD-1/PD-L1 inhibitors or docetaxel as first-line therapy
- 5. What was the approximate median PFS observed with adagrasib in patients with previously treated advanced NSCLC harboring a KRAS G12C mutation in the Phase III KRYSTAL-12 study?**
 - a. 2.1 months
 - b. 3.5 months
 - c. 5.5 months**
 - d. 9.3 months